FDA Approves Neoadjuvant Nivolumab/Chemo for Early-Stage NSC

The pathologic complete response rate was 24% versus 2.2% with chemotherapy alone.

Related Keywords

Mark Awad , Drug Administration , Dana Farber Cancer Institute , Bristol Myers Squibb , Lung Cancer , Ung Carcinoma , Ancer Lung , Non Small Cell Lung Cancer , Nsclc , Cancer , Alignant Neoplasia , Arcinoma , Chemotherapy , Neoadjuvant , Combination Chemotherapy , Biologic Therapy In Cancer , Iological Therapy In Cancer , Iologics Cancer , Biologic Therapy , Platinum , Pneumonia , Nausea , Constipation , Fatigue , Clinical Research , Clinical Trials , Linical Studies , Medical Literature , Books , Textbooks , O ,